Latest Applied genetics Stories
MOUNTAIN VIEW, Calif., Dec. 13, 2012 /PRNewswire/ -- 23andMe, the leading personal genetics company, today announced the availability of Ancestry Composition, a new feature that provides state-of-the-art geographic illustration of an individual's ancestral origins. Using 22 reference populations, the feature indicates what percent of a person's ancestry comes from various regions around the world. The analysis includes DNA inherited from all ancestors on both sides of the family....
AMSTERDAM, The Netherlands, December 5, 2012 /PRNewswire/ -- uniQure B.V., a leader in the field of human gene therapy, today announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. (ASX: BLT) giving uniQure access to Benitec's proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington's disease. In return, uniQure granted Benitec non-exclusive access to the Company's AAV5 delivery technology for the development of a ddRNAi therapy for...
MOUNTAIN VIEW, Calif., Dec. 4, 2012 /PRNewswire/ -- 23andMe has received grants totaling $573,000 from the National Institutes of Health (NIH) to support three projects that utilize 23andMe's unique web-based research platform. These include projects to better understand the genetics of allergies; to assess accuracy of new sequencing technologies in clinical applications; and to develop tools that will take advantage of the genotypic and phenotypic information in the 23andMe...
WINFIELD, Ill., Nov. 20, 2012 /PRNewswire/ -- Ancestry Graphics & Printing has unveiled their holiday plans to allow more genealogists and family historians to see their years of research transformed into a printed family tree chart and to receive a free bonus gift as well. To introduce more families with a genealogy buff in the household to their service, Ancestry Graphics & Printing is selling vouchers this holiday season in increments of $25 to fit any budget. The...
AMSTERDAM, The Netherlands, November 2, 2012 /PRNewswire/ -- - Glybera [http://www.uniqure.com/uploads/Glybera 2pp Factsheet_lr.pdf ] becomes the first gene therapy approved by regulatory authorities in the Western world - First medication approved for patients with rare metabolic disorder Lipoprotein Lipase Deficiency - Commercial roll-out to begin second half of2013 - Validates uniQure's unique AAV-based...
Connie K. Ho for redOrbit.com – Your Universe Online Researchers from Oregon Health and Science University (OHSU) recently revealed a new gene therapy method that can successfully prevent particular inherited diseases. The scientists worked under the college’s Oregon National Primate Research Center as well as the Department of Obstetrics and Gynecology at OHSU and were able to complete the procedure in human cells. With the findings of the study, the new gene therapy will provide new...
SOUTH EASTON, Mass., Oct. 18, 2012 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that two research groups have reported on the ability of the Company's Pressure Cycling Technology ("PCT") Platform to improve the detection of DNA in challenging forensic samples. The studies were presented by scientists from the Institute of Applied Genetics, Department of Forensic and Investigative Genetics, University of North Texas Health Science...
MOUNTAIN VIEW, Calif., Oct. 15, 2012 /PRNewswire/ -- In a new theoretical study, 23andMe, the leading personal genetics company, developed a mathematical model which shows that family history and genetic tests offer different strengths. The study results suggest that both family history and genetics are best used in combination to improve disease risk prediction. The full results of the study have now been published online in the journal PLOS Genetics. Family history is most useful...
HOUSTON and SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- Lonza, a global leader in the field of viral therapy manufacturing, and Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that they have entered into a process transfer and GMP manufacturing agreement. Under the terms of the agreement, Lonza will manufacture cGMP-grade MYDICAR (AAV1/SERCA2a) for use in future clinical...
HELSINKI, Finland and SAN FRANCISCO, September 17, 2012 /PRNewswire/ -- MediSapiens launches first-in-kind fully integrated and unified cloud computing application that harnesses the power of Big Data and enables knowledge-based drug discovery and repositioning for personalized genomics. This application, called OncoGenomics Explorer, is the next stage of bioinformatics applications for drug discovery. Unlike other cloud computing genomics applications, the Oncogenomics...
